Endovascular treatment for mycotic aneurysm using pyoktanin-applied devices

Kei Kazuno1*, Hajime Kinoshita2, Mariko Hori1, Takamichi Yosizaki1, Atsusi Tamura1, Hiroshige Sato1 and Seiichiro Murata1

Abstract

Background: Mycotic thoracic aortic aneurysm is an extremely rare but serious disease because it can easily rupture and has a high mortality rate. The standard therapy for it comprises graft replacement and debridement using systemic antibiotics; nonetheless, this has a high mortality rate and complications. Endovascular aortic repair is considered a bridging therapy before open surgery. However, we have used it at our institution for the radical treatment of mycotic thoracic aortic aneurysm utilizing pyoktanin (methylrosanilide chloride)-applied devices. Thus, the aim of this study was to report our clinical experience with pyoktanin-applied thoracic endovascular aortic repair for the treatment of mycotic thoracic aortic aneurysm, including its effects.

Methods: From April 2017 to July 2019, we performed thoracic endovascular aortic repair using pyoktanin for eight cases of mycotic thoracic aortic aneurysm using Valiant®. During device preparation before insertion, pyoktanin was flushed from the side port instead of saline containing heparin.

Results: There were no operative deaths, recurrences of infection, or major complications. Two cases died from pneumonia and cancer; the other six cases were alive during the follow-up period.

Conclusions: Pyoktanin-applied thoracic endovascular aortic repair for mycotic thoracic aortic aneurysm treatment is effective. However, the appropriate use of antibiotics and bundled therapy is necessary at present.

Keywords: Aneurysm, Methylrosanilide chloride, Endovascular procedures, Thoracic surgery

Background

Although rare, mycotic thoracic aortic aneurysm (MTAA) is an extremely serious disease with a high rupture and high mortality rate. When only conservative therapy is provided, the mortality rate is believed to be over 80% (JCS Joint Working Group 2013). Therefore, treatment is generally based on surgery.

The basic surgical treatments include open aneurysm excision and aortic repair, debridement, and drainage coupled with the long-term administration of antibiotics. Thoracic endovascular aortic repair (TEVAR), a relative contraindication for MTAA, has previously been performed as a bridge therapy before open surgery or as an emergency surgery in cases such as ruptures. However, several cases have recently reported that TEVARs were performed for MTAA as elective surgery, with adequate outcomes and no recurrent infections (Isao et al. 2017). Nevertheless, there are still the problems of the infection focus remaining as a closure cavity and of postsurgical infection due to the device placed in the infection focus.

The Valiant® thoracic stent graft system (Medtronic, Santa Rosa, CA, USA) is our primary choice in our elective TEVAR, although it is also used in MTAA. Because the above-described problem of device infection remains, pyoktanin (methylrosanilide chloride) is applied to our graft prior to insertion to prevent infection. Thus far, this technique has been used in all MTAA cases in our institution, and all patients have survived at least 15 months after TEVAR, implying that pyoktanin renders a certain amount of protection against device infection.
Further, pyoktanin is easily prepared and stored. Moreover, stock can be quickly made for urgent or emergent surgery, making it convenient for use. Here we report our clinical experience with pyoktanin-applied TEVAR for the treatment of MTAA, including its effects. To the best of our knowledge, such an experience has not yet been reported.

Patients and methods

Study design and background

This was a retrospective single-institution study. The use of pyoktanin-applied TEVAR for MTAA has been approved by the ethics committee at our institution.

Previous reports have dealt with how to flush rifampicin (RFP) into surgical graft in graft replacement as a means of treating MTAA before performing the replacement (JCS Joint Working Group 2013; Koshikio et al. 2002). However, an investigation of the literature revealed that there were no reports of pyoktanin being used in surgical graft or stent-graft and no reports on techniques wherein pyoktanin is infused among reports of surgeries performed using TEVAR as a curative treatment for MTAA.

As shown below, we use pyoktanin at our institution when surgical graft or stent-graft is used at the site of infection, as we have found that the sustained efficacy for RFP is poor when surgical graft or stent-graft is used for MTAA.

Patient selection

Patients with MTAA who were admitted to our institution and for whom the decision was made to perform surgery underwent graft replacement that was infused with pyoktanin if it was determined that they could tolerate thoracotomy. TEVAR using stent grafts that were infused with pyoktanin was performed on patients who were determined unable to tolerate thoracotomy procedures, such as patients with numerous complications or a poor general condition. All patients meeting the above conditions were evaluated.

Pyoktanin-applied TEVAR procedure

We performed pyoktanin-applied TEVAR for eight MTAA cases. The clinical information for the eight cases is listed in Table 1.

Results

There were one female and seven male patients, with a mean age of 77.5 years. Three cases were complicated with diabetes mellitus, and three persons were hemodialysis patients. Major complaints included fever ($n = 2$), back pain ($n = 5$), and back pain associated with fever ($n = 1$). All patients presented with symptoms of infection in their blood test results at the time of their first visit to our hospital, including five patients who had previously received antibiotics at other hospitals. Three patients exhibited positive blood culture results at the time of hospitalization. No3 patient was detected *staphylococcus aureus*, No5 was detected *enterococcus faecalis* and No7 was detected *enterococcus faecium* from each blood cultures. The patients were administered antibiotics from the time of hospitalization and were treated to improve inflammation symptoms, which was monitored with regular computed tomography (CT) scans.

TEVAR was performed electively except for one emergency case because of an in-hospital rupture. The mean time from admission to TEVAR was 13.2 days (range: 7–18 days). All patients received surgery using pyoktanin-applied TEVAR under general anesthesia. All surgeries were successful with no complications. Following the surgery, patients continued receiving intravenous antibiotics until the white blood cell count fell within the normal range or C-reactive protein was ≤5. Thereafter, oral antimicrobial therapy was continued. Patients were discharged once it was confirmed that there were no recurrent signs of inflammation and no bacterial growth in their blood culture. Oral antimicrobial therapy was continued until the signs of inflammation were completely resolved at the patient’s visit. The mean time from surgery to discharge was 26.5 days (range: 12–66

| No | Age | Sex | DM | HT | HD | At admission | Pre-admission Abx | Rupture after admission |
|----|-----|-----|----|----|----|-------------|-------------------|-----------------------|
|    |     |     |    |    |    | Fever, Pain | WBC, CRP | Blood culture |                      |
| 1  | 73  | male| +  |    |    | +           | 5700, 1.88 | +         |                      |
| 2  | 78  | male| +  |    |    | +           | 22,900, 30.4 | +         |                      |
| 3  | 70  | female| +  |    |    | +           | 10,500, 8.71 | +         |                      |
| 4  | 82  | male| +  | +  |    | +           | 9800, 5.67 | +         |                      |
| 5  | 85  | male| +  | +  |    | +           | 12,500, 10.79 | +         |                      |
| 6  | 85  | male| +  | +  |    | +           | 5900, 5.59 | +         |                      |
| 7  | 87  | male| +  | +  |    | +           | 12,400, 17.53 | +         |                      |
| 8  | 60  | male| +  |    |    | +           | 12,700, 16.1 | +         |                      |
days). The mean follow-up time from surgery was 28.4 months (range: 13–64 months) (Table 2).

Case study for patient #6
Case #6 was an 85-year-old male who currently visits another hospital for hemodialysis treatment. An unknown fever was observed, with inflammation signs in a blood test at the previous hospital. Following hemodialysis, treatment with intravenous antibiotics was initiated, but there was no improvement. *Escherichia coli* were detected in the patient’s blood culture, and he was referred to our institution. His CT scan at the time of hospitalization showed a multiloculated cyst-like distal arch aneurysm, with a maximum diameter of 74 mm (Fig. 1a, b). Although the imaging findings suggested an impending rupture, the patient noticed no symptoms. Considering that the signs of inflammation were evident, meropenem (0.5 g/d) and daptomycin (350 mg/d) were initiated. After the administration of these antibiotics, the signs of inflammation improved, and the fever was reduced. However, the signs of inflammation were not completely resolved, and a CT exam on day 13 revealed a further enlargement of the aneurysm, which led to urgent TEVAR surgery.

TEVAR was performed with Valiant® VAMC3228C150TJ under general anesthesia. Typically, saline containing heparin is flushed from the side port as a pretreatment prior to device insertion. In this case, however, pyoktanin was used instead of saline containing heparin. Then, the device was deployed as per the usual procedure.

Following the surgery, the administration of meropenem and daptomycin was continued. Daptomycin was discontinued on postsurgical day 10, and meropenem was discontinued on postsurgical day 29, based on the signs of inflammation and blood culture results. Oral antimicrobial therapy then commenced, and after confirming that there were no recurrent signs of inflammation, the patient was discharged on postsurgical day 41. A postoperative enhanced CT showed no leakage to the aneurysm (Fig. 2a, b). Currently, at 18 months postsurgery, the patient visits our hospital regularly and shows no recurrent signs of inflammation. Furthermore, the imaging exam shows a reduction in the aneurysm size.

**Discussion**

Infected aneurysm, a disease reported by Osler for the first time in 1885, is a general term for describing aneurysms caused by infection and infection-affected pre-existing aneurysms (JCS Joint Working Group 2013). It is a relatively rare disease, accounting for only 0.5%–1.3% of all aortic aneurysms (Muller et al. 2001). The mortality rate of 23.5%–37% is significantly high compared to its non-infectious counterpart. No treatment has been established so far. The only current approach to treatment is planning therapy for the individual patient while taking into account the condition of the aneurysm and the patient’s background (Muller et al. 2001).

Causes include infected endocarditis, bacterial arteritis, infection of preexisting aortic aneurysms, and traumatic or iatrogenic factors. Although there is research reporting that *Salmonella, E. coli, Staphylococcus*, *Streptococcus*, etc., were detected as the causative bacteria and > 70% of cases had positive culture results, other reports show that > 50% of the cases had negative culture results. It should be noted that negative results in the blood culture do not negate the possibility of MTAA (Isao et al. 2017).

Before treating the MTAA, a sufficient and required dose of antibiotics should first be administered to preferentially suppress and infection prior to surgery. Because the mortality rate is reported to be 54.5%–96% if treated with antibiotics alone, the presurgical use of antibiotics, wherever applicable, has been recommended as a standard procedure (Hsu et al. 2004; Forbes and Harding 2006). Previously, the surgical procedure included the removal of infected tissues by excising the aneurysm, aortic repair, and omental wrapping (Kan et al. 2007; Satoshi et al. 2013). However, although the outcome

| No | Duration to ope. (d) | Hospital stay (d) | Antibiotic duration after ope. IV (d) | Oral (m) | Follow-up period (m) | Outcome |
|----|---------------------|------------------|--------------------------------------|----------|---------------------|--------|
| 1  | 12                  | 12               | 5                                    | 2        | 64                  | alive  |
| 2  | 17                  | 14               | 7                                    | 3        | 39                  | alive  |
| 3  | 7                   | 28               | 19                                   | 6        | 30                  | death from pneumonia |
| 4  | 10                  | 14               | 10                                   | 3        | 29                  | alive  |
| 5  | 14                  | 66               | 35                                   | 4        | 19                  | alive  |
| 6  | 15                  | 29               | 21                                   | 6        | 18                  | alive  |
| 7  | 13                  | 28               | 12                                   | 6        | 15                  | death from pneumonia |
| 8  | 18                  | 21               | 11                                   | 3        | 13                  | alive  |
varied depending on the preoperative systemic conditions, many cases involved poor preoperative conditions with extensive surgical invasion, and the in-hospital and one-year mortality rates were reported to be 11% and 25%, respectively, which cannot be considered a satisfactory outcome (Hsu et al. 2004). Recently, indications for TEVAR, which is a minimally invasive endovascular treatment, have been increasing for atherosclerotic thoracic aortic aneurysms. Since the introduction of aortic stent grafts for infected abdominal aortic aneurysms by Semba et al. for the first time in 1998, better outcomes in combination with appropriate antibiotic therapy have been reported for infected aortic aneurysms, and this is considered an effective alternative to the conventional strategy (Kan et al. 2010).

TEVAR has been, in principle, considered a relative contraindication for infected aortic aneurysms from the viewpoint of the insertion of an artificial device into the infected site and has been performed in cases where invasion by surgical revascularization was impractical owing to a poor systemic condition or as an emergency measure before open surgery (Forbes and Harding 2006). However, because MTAAs are in saccular aneurysmal changes usually, TEVAR is easier to manipulate and quickly stops hemorrhages in rupture cases. Thus, many believe that TEVAR is useful for ruptured cases associated with infection (Bell et al. 2003). However, it should be noted that the postsurgical course may vary, and postsurgical administrations of antibiotics to prevent the prolongation and recurrence of infection, along with careful follow-ups, are necessary.

Kan et al. investigated 48 cases where stent grafts were used for infected aortic aneurysms and reported surgical deaths in 10.4% (five cases), with a one-year survival rate of 94% (infection-treated group) compared to 39% (infection-non-treated group) (Kan et al. 2010). Another
study reported a 30-day mortality rate of 5.6% (Kan et al. 2007). In Europe, TEVAR was performed in 130 cases of infected aortic aneurysms at 16 centers, reporting additional surgery by replacing the aneurysm with synthetic graft in 5% of cases, with a one-year survival rate of 91% and an infection-related mortality rate of 19% (Sörelüs et al. 2014). Other reports suggest the validity of stent grafting combined with surgical debridement (Prokakis et al. 2008). There are also reports of cases where antibacterial agent-treated grafts were used.

In surgery for MTAA, expanded polytetrafluoroethylene (ePTFE) grafts and RFP-soaked ePTFE grafts have been used, and there are reports on such usage. Narasimhan et al. reported that ePTFE graft did not allow methicillin-resistant Staphylococcus aureus (MRSA) and E. coli to pass through the vessel wall, even when their biofilm was formed on the vessel surface (Narasimhan et al. 2010). As far as our research is concerned, there were no reports of increased postsurgical infections between the use of ePTFE graft and non ePTFE grafts (Taichi et al. 2016; Hai Lei and Yui Che 2018). This suggests that there will be no differences among devices used in TEVAR for MTAA, although the results are not conclusive because the anti-infection properties of these devices have not been investigated.

Studies have reported on the use of grafts treated with RFP, an antimicrobial agent. Because RFP strongly binds to gelatin and is effective across a broad spectrum, it is used in gelatin-coated synthetic vessels. A decrease in the mortality rate and the recurrent infection rate by REP-soaked grafts has been reported. However, in Japan, the RFP solution is not commercially available and is currently prepared in-hospital at the time of use. Although the RFP solution is available overseas, in Japan, the RFP solution must be prepared from powders. Dissolving RFP powders is an awkward and rather laborious task. Another problem is its short lifetime in solution; consequently, the effectiveness of RFP is lost during long-term storage. In addition, a report suggests that while RFP is effective on weak bacteria, such as Staphylococcus epidermidis, its effects on MRSA are unknown, because MRSA can be tolerated immediately (Koshiko et al. 2002).

At our institution, to treat mediastinitis after graft replacement, the cleaning of the lesion and removing of infected tissues have been extensively performed before omental wrapping as much as possible in addition to administering antibiotics. Pyoktanin has been applied to the artificial vessel at the time of cleaning the lesion to control the local infection. Pyoktanin has been used as an antibacterial agent for grafts at our institution because in addition to the fact that we have not adopted the use of RFP, RFP requires time-consuming preparation as described above, and the cost of pyoktanin is lower than that of RFP.

Pyoktanin (methylrosanilide chloride) is a synthetic dye that belongs to the triphenylmethane family, and it has an antiseptic effect. It was first synthesized in the 1860s and used for medical treatment by Stilling from 1890 onward (Akira et al. 2016). Pyoktanin is considered to have an antibacterial effect against gram-positive bacteria, particularly staphylococci and diphtheria bacilli, and is widely used for skin ulcers and decubitus infections (Alexander and Jack 2013). Its primary effect is the inhibition of cell wall and glutamine synthesis at sites different from penicillin. Even in MRSA, Pyoktanin is very effective antiseptic effect (Akira et al. 2015). Salmonella are gram-negative anaerobic bacteria which is one of the main bacteria with mycotic aneurysm. Although there is not examined Salmonella, there is research that pyoktanin is effective against Gram-negative (Ichino et al. 2015), so we thought that pyocyanin might be effective against MTAA, so we decided to use it for MTAA at our institution.

Pyoktanin is recommended for administration at a 0.1% concentration and provides a relatively stable efficacy against MRSA without causing tissue damage. Maley et al. reported that at a concentration of 0.1%, pyoktanin has almost no side effects and can be safely used (Maley and Arbiser 2013). Disinfectant solutions, such as RFP and povidone-iodine, quickly weaken and lose their potency in the presence of albumin and in regions with a large amount of exudate, whereas pyoktanin can be expected to still render its effects, even in the presence of albumin, and it is known for its persistent and stable antibacterial effects that can last 24 h in regions with a large amount of exudate (Jun and Yoshihiro 1992).

In our institution, a 0.1% formulation of pyoktanin is prepared by dissolving the powders in a solvent under sterile conditions. It can be readily prepared, even for emergency surgery, because the time required for preparation is only around 1 h, including the time for sterilizing the solvent. When used in surgery, the solvent is tested in culture prior to use to confirm its sterility.

In our institution, 151 cases of TEVAR surgery, including MTAA cases, aortic dissections, and aortic ruptures, were performed from April 2014 to July 2018. There were four cases of death (2.6%) (including two rupture cases), two cases of complications with cerebral infarction (1.3%), and two cases of complications with spinal infarction (1.3%). Valiant was used in 112 (74%) of the cases. Although there are many commercial products available for TEVAR and their superiority/inferiority cannot be easily compared, we believe that Valiant is effective in various ways, such as the ease of handling, precise deployment at the placement site, tracking performance in the aorta, and strength of the radial force. MTAA was performed with Valiant without problems in all cases.
There is no academic paper that describes drug penetration methods when treating MTAA with TEVAR for the purpose of clinical practice. However, from personal experience, when using the RFP solution, the stent was deployed once to allow RFP to penetrate into the graft and then stored into the catheter again to perform the insertion for delivery. Furthermore, re-insertion is troublesome, and there are potential risks of damage to the graft at the time of re-insertion and problems at the time of deployment that are due to handling during re-insertion. At our institution, we permeate the drug into the graft by injecting pyoktanin via a side port for evacuating the air. This is easily performed without requiring the procedures mentioned above. However, we do not know whether the pyoktanin is uniformly and securely applied to the device. Thus, the actual extent of permeation of the pyoktanin application was examined by injection in vitro.

Flushing with 40-mL saline via a side port is recommended by the manufacturer. There is no difference in viscosity between the saline and pyoktanin solution; thus, we attempted flushing 40-mL pyoktanin via a side port. Developments after a while confirmed that pyoktanin had penetrated most areas (≥98% in terms of surface area ratio), except for the wrinkled part of the Valiant® graft (Fig. 3a, b). Next, 80-mL pyoktanin was flushed, and the device was removed. The graft was more intensely stained with pyoktanin, although there was no difference in the degree of penetration in terms of surface area compared to the 40-mL flush (Fig. 4). Crumpling the outer sheath at the time of pyoktanin flush did not change the degree of penetration in terms of surface area (Fig. 5a, b). In both cases, however, pyoktanin penetrated the area over time into areas where pyoktanin had been absent. This same phenomenon is hypothesis to also occur in the human body.

While there is a correlation between the pyoktanin concentration and the antibacterial activity, there is no correlation between the pyoktanin dose and its antibacterial effect. Although an 80-mL flush can penetrate the device at a stronger concentration, this fact suggests that the 40-mL flush can render the same antibacterial effect as an 80-mL flush. Therefore, there will be no problem with using pyoktanin for MTAA at a flush volume of

![Fig. 3](image-url)
40-mL, which is equivalent to the same amount of saline recommended by the manufacturer for normal operation.

No patients in this study exhibited any recurrent signs of infection. However, it is possible that in cases of strong infection, concentrated infusions of pyoktanin alone might be insufficient. Because this treatment requires that an artificial object be inserted at the site of infection, physicians must constantly check for any signs of further infection postoperatively.

Our study had some limitations. First, the sample size was small, and our results need to be confirmed across a larger population. Second, this was a single-institution study, and future investigations should be performed across multiple institutions. And last, there are not able to compare the use group and non-use group of pyoktanin. This would entail the use of a specific standardized protocol for all institutions, so that the results are comparable.

Our results suggest that pyoktanin-applied TEVAR for MTAA treatment can be easily implemented and is an effective treatment. Although the appropriate use of antibiotics and bundled therapy are necessary at the present time, pyoktanin-applied TEVAR can serve as an effective treatment for MTAA. Further investigation with more clinical cases is planned at our institution.

---

**Fig. 4** There was no difference between the amount of stained surface area between the 40-mL flush and 80-mL flush of pyoktanin.

**Fig. 5** Comparison of the dyeing condition on the device between crumpling the outer sheath (a) and not crumpling the outer sheath (b). No difference was noted between the two methods.
Conclusions
MTAA is high mortality disease and TEVAR for MTAA as radical therapy is still controversially method. But pyoktanin-applied TEVAR for MTAA is effective we thought, and the appropriate use of antibiotics and bundled therapy is necessary at present.

Abbreviations
CT: Computed tomography; MRSA: Methicillin-resistant Staphylococcus aureus; MTAA: Mycotic thoracic aortic aneurysm; TEVAR: Thoracic endovascular aortic repair; RFP: Rifampicin

Acknowledgements
Not applicable.

Authors’ contributions
All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
This study has been approved by the ethics committee at our institution.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cardiovascular Surgery, Itabashi Chuo Medical Center, 2-12-7 Azusawa Itabashi-ku, Tokyo 174-0051, Japan. 2Department of Cardiovascular Surgery, Tokushima Prefectural Central Hospital, 1-1-10 Kuramoto-cho Tokushima-shi, Tokushima 770-8539, Japan.

Received: 1 June 2020 Accepted: 14 August 2020
Published online: 08 November 2020

References
Akira N, Hironori O, Kunio N (2015) A case of MRSA empyema with fistula and nephritic syndrome successfully treated with detergent using 0.1% pyoktanin solution. JACS 30:159–163
Akira N, Hironori O, Kunio N (2016) A case of MRSA empyema with fistula and nephritic syndrome successfully treated with detergent using 0.1% Pyoktanin solution. JACS 30:159–163
Alexander MM, Jack LA (2013) Gentian violet: A 19th century drug re-emerges in the 21st century. Exp Dermatol 22:775–780
Bell RE, Taylor PR, Aukett M, Evans GH, Reidy JF (2003) Successful endoluminal repair of an infected thoracic pseudoaneurysm caused by methicillin-resistant Staphylococcus aureus. J Endovasc Ther 10:29–32
Forbes TL, Harding GE (2006) Endovascular repair of Salmonella-infected abdominal aortic aneurysms: a word of caution. J Vasc Surg 44:198–200
Hai Lei L, Fu Che C, Stephen WC (2018) Current evidence on management of aortic stent-graft infection: a systematic review and meta-analysis. Ann Vasc Surg 51:306–313
Hsu RB, Chen RJ, Wang SS, Chu SH (2004) Infected aortic aneurysms: clinical outcome and risk factor analysis. J Vasc Surg 40:30–35
Ichino K, Haruka S, Tetsuya M (2015) Bactericidal effect of crystal violet on various clinical isolates. Toidashi 73:19–26
Isao N, Akino U, Ry O (2017) Thoracic endovascular aortic repair for mycotic thoracic aortic aneurysm. J Jpn Soc Intensive Care Med 24:126–130
JCS Joint Working Group (2013) Guidelines for diagnosis and treatment of aortic aneurysm and aortic dissection (JCS 2011). Circ J 77:789–828
Jun Q, Yoshihiro M (1992) Effect of methyrosanilinium chloride to MRSA nasal carriers. Kansenshogaku Zasshi 66:376–381
Kan CD, Lee HL, Luo CY, Yang YJ (2010) The efficacy of aortic stent grafts in the management of mycotic abdominal aortic aneurysm-institute case management with systemic literature comparison. Ann Vasc Surg 24:433–440
Kan CD, Lee HL, Yang YJ (2007) Outcome after endovascular stent graft treatment for mycotic aortic aneurysm: a systematic review. J Vasc Surg 46:906–912
Koshiko S, Sasa Jima T, Muraki S, Azuma N, Yamazaki K, Chiba K, Tachibana M, Inaba M (2002) Limitations on the use of rifampicin-gelatin grafts against virulent organisms. J Vasc Surg 35:779–785
Maley AM, Arbiser JL (2013) Gentian violet: a 19th century drug re-emerges in the 21st century. Exp Dermatol 22:775–780
Muller BT, Wegener OR, Grabitz K, Pillny M, Thomas L, Sandmann W (2001) Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg 33:106–113
Narasimhan S, Aslam S, Lin PH, Bechta CF, Mansouri MD, Darouiche RO (2010) Bacterial translocation across ePTFE vascular graft surfaces. J Inf Secur 60:486–490
Promakis K, Koletis E, Apostolakis E, Dedellas P, Dougenis D (2008) Aortooesophageal fistulas due to thoracic aorta aneurysm: surgical versus endovascular repair. Is there a role for combined aortic management? Med Sci Monit 14:RA48–RA54
Satoishi Y, Ryoko A, Yuya K, Hitoshi I, Yukio K (2013) Potential role of omental wrapping to prevent infection after treatment for infectious thoracic aortic aneurysms. EJCTS 43:1177–1182
Sorelius K, Mani K, Björck M, Sedvå P, Wahlgren OM, Taylor P, Clough RE, Lyons O, Thompson M, Brownrigg J, Ivanov V, Davis M, Jenkins MP, Jaffer U, Bown M, Rancic Z, Mayer D, Brukwall J, Gawenda M, Kölbl T, Jean-Baptiste E, Moll F, Berger P, Lupis CD, Moulaakis KG, Langenköld M, Roos H, Larson T, Prouzi R, Warhainen E, European MAA collaborators (2014) Endovascular treatment of mycotic aortic aneurysms: a European multicenter study. Circulation 130:e169–e242
Takai K, Masanori H, Shunichi K, Joji H, Minoru Y, Tadashi I (2016) Post-thoracic endovascular aortic repair complicated with mycotic aneurysm rupture, repaired by redo thoracic endovascular aortic repair. Ann Vasc Surg 33:228e1–228e4

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.